研究显示,Paldlovid可能帮助一些长期的COVID病人,但还需要做更多的研究。 Study suggests Paxlovid may help some long COVID patients, but more research is needed.

San Francisco哥伦比亚大学的一项研究发现,扩大使用抗病毒药物Patlovid可能使一些具有长期COVID的病人受益,这一疾病影响到大约1 760万美国人。 A study by UC San Francisco found that extended use of the antiviral drug Paxlovid may benefit some patients with long COVID, a condition affecting about 17.6 million Americans. 在13名病人中,有5人报告说其症状得到持续改善。 Among 13 patients, five reported lasting improvements in their symptoms. 然而,该研究指出,需要进一步研究,以确定哪些病人可能受益,并确定最佳治疗期限。 However, the study noted the need for further research to identify which patients might benefit and to determine the optimal treatment duration. 这项研究突出说明了在治疗长期COVID方面持续存在的挑战,这一疾病有200多个报告的症状。 The research highlights the ongoing challenges in treating long COVID, a condition with over 200 reported symptoms.